Latest Breaking News On - Hepion pharmaceutical - Page 9 : comparemela.com

(2) EDISON, NJ / ACCESSWIRE / February 10, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)( Hepion ), a clinical stage biopharmaceutical company focused on Artificial Intelligence ( AI )-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ( NASH ) and liver disease, today announced the appointment of Todd M. Hobbs, M.D., to the newly created position of Chief Medical Officer ( CMO ), effective February 16, 2021. In this role, Dr. Hobbs will help lead Hepion s engagement with the U.S. Food and Drug Administration ( FDA ), global and national thought leaders, key policymakers, and professional associations. Dr. Hobbs joins Hepion from Novo Nordisk Inc., one of the world s leading healthcare companies. His 16 years of progressive experience at Novo Nordisk includes positions ranging from field medical affairs leadership at the start of his corporate career through to his most recent role as North American Chief Medical Officer and Vice President.

University of louisvilleUnited statesStephen kilmerToddm hobbsRobert fosterAmerican medical group associationUniversity of louisville school medicineDrug administrationHepion pharmaceuticals incExchange commissionHepion pharmaceuticalsUniversity of pennsylvania wharton school businessHepion pharmaceuticals investor relationsNovo nordiskNovo nordisk incArtificial intelligence